Spanish pharmacies are experiencing unprecedented consolidation. This guide analyses the regulatory framework, valuation methods and the sale process for pharmacy owners and pharmaceutical groups operating in Spain.
The Spanish pharmacy sector is unique in the business landscape. It combines strict regulation that limits competition with solid, predictable profitability, making it one of the most attractive asset classes for professional investors. In recent years, the sector has experienced a consolidation process that has reshaped the country’s pharmaceutical map.
For the pharmacist-owner contemplating the sale of their pharmacy, understanding the process’s particularities is essential. This is not a conventional business sale: regional regulation, ownership requirements and administrative authorisations add layers of complexity that require planning and specialist advice.
Pharmacies have characteristics that make them particularly interesting for professional investors.
Predictable, recurring revenue. A well-located pharmacy generates a stable income stream, with a prescription component that provides an almost guaranteed demand base. The parapharmacy, dermocosmetics and complementary services segments add a growth component with higher margins.
Regulatory barrier to entry. The limitation on the number of pharmacies per pharmaceutical zone protects the existing operator from direct competition. It is a natural barrier that gives the business intrinsic value independent of management quality.
Consolidation underway. Pharmaceutical groups are acquiring individual pharmacies at a growing pace. Joint purchasing platforms, centralised services and professionalised management improve margins and create synergies that the individual pharmacist cannot achieve alone.
Population ageing. Spain’s demographics ensure sustained growth in demand for pharmaceutical services over the coming decades. This is a sector with structural tailwinds.
The buyer market for pharmacies in Spain has become notably sophisticated.
Pharmaceutical groups. The most active buyers. They operate under clustering models that allow them to share centralised services (purchasing, marketing, training, financial management) while maintaining individual ownership of each pharmacy in compliance with regulations. They seek pharmacies with good locations and operational improvement potential.
Investment funds. They have entered the sector through structures that respect ownership regulations. They typically invest in clustering platforms and seek scale to generate efficiencies. Their typical investment horizon is 5 to 7 years.
Entrepreneurial pharmacists. Young professionals seeking their first pharmacy or their second to start building a group. They usually require bank financing, which may extend the process but not necessarily the price.
Pharmaceutical cooperatives. Some cooperatives have developed pharmacy acquisition and management programmes that offer a sale alternative with guaranteed model continuity.
The valuation of a pharmacy uses sector-specific criteria that differ from other businesses.
Revenue multiple. The most commonly used method as a first approximation. Typical ranges in Spain are:
| Annual revenue | Revenue multiple |
|---|---|
| Under €500,000 | 1.0 – 1.5x |
| €500,000 – €1,000,000 | 1.3 – 1.8x |
| €1,000,000 – €2,000,000 | 1.5 – 2.2x |
| Over €2,000,000 | 1.8 – 2.5x |
EBITDA multiple. A more precise indicator that accounts for actual profitability. Typical multiples range from 6 to 10 times EBITDA, depending on location, growth potential and revenue quality.
Discounted cash flow. For larger pharmacies or groups, it is common to complement multiples with a discounted cash flow analysis that captures growth prospects and necessary investments.
Location and pharmaceutical zone. The assigned population density, proximity to health centres, premises visibility and accessibility determine revenue potential and, consequently, value.
Sales composition. A pharmacy with a high percentage of parapharmacy and dermocosmetic sales (higher margin) is valued more highly than one weighted towards NHS prescriptions (lower margin but greater stability).
Premises condition. The pharmacy operates in premises that may be owned or leased. If leased, the rental contract conditions directly affect the value. An above-market rent reduces the business’s value.
Authorisation rights. The administrative operating licence has inherent value. In areas with demand for new pharmacies and no available licences, this intangible value can be significant.
Selling a pharmacy involves a specific administrative process that is worth understanding in advance.
Before initiating the sale, it is advisable to organise the documentation the buyer and the administration will require: financial statements for the last three to five years, a certificate of the administrative authorisation’s status, current contracts (lease, employees, suppliers), an updated inventory, and documentation on recent refurbishments or investments.
Transferring a pharmacy requires authorisation from the health authority of the relevant autonomous community. Requirements and timescales vary significantly between regions. Specialist advice on the applicable regional legislation is indispensable.
A professional buyer will conduct a review that includes, beyond the standard financial and legal elements:
The most common structure is the purchase of the company shares of the entity holding the pharmacy, which includes the administrative licence, goodwill, stock and business assets. In some cases it is structured as a business transfer. The choice depends on tax factors and the company’s balance sheet position.
Divergent regional regulation. Each autonomous community has its own rules on pharmacy transfers. What works in Madrid may not work in Catalonia or Andalusia. Specialist legal advice is not optional — it is essential.
Pharmacist ownership requirement. The requirement that the holder be a registered pharmacist limits the universe of direct buyers, though corporate structures have broadened investment options.
Stock valuation. A pharmacy’s stock can represent a significant amount (typically 8% to 12% of annual revenue). Valuing and treating stock in the purchase price is a standard negotiation point.
Team retention. In pharmacies with specialised services (compounding, advanced pharmaceutical care), the continuity of qualified staff is critical to maintaining the business’s post-sale value.
At Blue Mountain we analyse the pharmaceutical sector with a long-term investor’s perspective. We understand that a pharmacy is not merely a business: it is an essential service with a healthcare and social dimension that must be preserved.
Our interest focuses on well-managed pharmacies and pharmaceutical groups with solid locations and growth potential through complementary services and operational improvement. We value team stability, quality of patient care and the reputation built over years of community service.
The process begins with a confidential conversation where we listen to the owner’s motivations and share our sector vision. There is no pressure and no obligation. If both parties see value in moving forward, we develop a valuation proposal tailored to each pharmacy’s specifics.
If you own a pharmacy or pharmaceutical group and are exploring your options, let’s talk.
By Blue Mountain Capital
By Blue Mountain Capital
By Blue Mountain Capital
If you wish to explore a potential collaboration or present an investment opportunity, we invite you to contact us. We guarantee absolute confidentiality in all our conversations.